Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine

Vaccine

Volumn 29, Issue 41, 2011, Pages 7173-7181

  Yan, Jian ^b   Corbitt, Natasha ^a   Pankhong, Panyupa ^a   Shin, Thomas ^a   Khan, Amir ^b   Sardesai, Niranjan Y ^b   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Inovio Pharmaceuticals   (United States)

Author keywords

Cellular immune responses; Clade C; Consensus; Envelope; HIV 1

Indexed keywords

CD5 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN E; P96ZM651 GLYCOPROTEIN GP 140 CD5 ANTIGEN; PROTEIN EY3E1 C; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CODON; CONSENSUS; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; CYTOPLASM; DNA IMMUNIZATION; DNA SEQUENCE; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FEMALE; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA SEQUENCE; RNA STRUCTURE; SEQUENCE ANALYSIS; T LYMPHOCYTE; VACCINATION; VIRUS GENE;

AIDS VACCINES; ANIMALS; CONSENSUS SEQUENCE; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV-1; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 80052498736     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.076     Document Type: Article

References (34)

1. Esparza J., Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?. Lancet 2000, 355:2061-2066.
2. Novitsky V., Smith U.R., Gilbert P., McLane M.F., Chigwedere P., Williamson C., et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?. J Virol 2002, 76:5435-5451.
3. McCutchan F. Understanding the genetic diversity of HIV-1. Aids 2000, 14:S31-44.
4. Kober B., Gaschen B., Yusim K. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001, 58:19-42.
5. Choudhury S.M., Montano M.A., Womack C., Blackard J.T., Maniar J.K., Saple D.G., et al. Increased promoter diversity reveals a complex phylogeny of human immunodeficiency virus type 1 subtype C in India. J Hum Virol 2000, 3:35-43.
6. Novitsky V., Montano M.A., McLane M.F., Renjifo B., Vannberg F., Foley B., et al. Molecular cloning and phylogenetic analysis of HIV-1 subtype C: a set of 23 full-length clones from Botswana. J Virol 1999, 73:4427-4432.
7. van Harmelen J., Williamson C., Kim B., Morris L., Carr J.K., Abdool A.J., et al. Characterization of full length HIV-1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses 2001, 17:1527-1531.
8. Ellenberger D.L., Li B., Lupo L.D., Owen S.M., Nkengasong J., Kadio-Morokro M.S., et al. Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology 2002, 302:155-163.
9. Gao F., Bhamarapravati N., Gaschen B., Taylor J., Moore J.P., Novitsky V., et al. Consensus and ancestral state HIV vaccines. Science 2003, 299:1517-1518.
10. Nickle D.C., Jensen M.A., Gottlieb P., Shriner D., Learn G.H., Rodrigo A.G., et al. Consensus and ancestral state HIV vaccines. Science 2003, 299:1515-1517.
11. Gao F., Weaver E.A., Lu Z., Li Y., Liao H.X., Ma B., et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005, 79:1154-1163.
12. Yan J., Yoon H., Kumar K., Ramanathan M.P., Corbitt N., Kutzler M., et al. Enhanced diversity and magnitude of cellular immune responses elicited by a novel engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther 2007, 411-421.
13. Chattergoon M.A., Robinson T.M., Boyer J.D., Weiner D.B. Specific immune induction following DNA-based immunization through in vivo transfection and activatiion of macrophages/antigen-presenting cells. J Immunol 1998, 160:5707-5718.
14. Girard M.P., Mastro T.D., Koff W.C. Vaccine 2003, Elsevier Publications. 4th ed.
15. McMichael A.J., Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?. Nat Rev Immunol 2002, 2:283-291.
16. Lu S., Santoro J.C., Fuller D.H., Haynes J.R., Robinson H.L. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 1995, 209:147-154.
17. Lu S., Wyatt R., Richmond J.F., Mustafa F., Wang S., Weng J., et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 1998, 14:151-155.
18. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998, 72:1497-1503.
19. Deml L., Bojak A., Steck S., Graf M., Wild J., Schirmbeck R., et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 gag protein. J Virol 2001, 75:10991-11001.
20. Schneider R., Campbell M., Nasioulas G., Felber B.K., Pavlakis G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 1997, 71:4892-4903.
21. Muthumani K., Zhang D., Dayes N.S., Hwang D.S., Calarota S.A., Choo A.Y., et al. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology 2003, 314:134-146.
22. Yang J.S., Kim J.J., Hwang D.S., Choo A.Y., Dang K., Maguire H., et al. Induction of potent Th1-Type immune responses from a novel DNA vaccine for West Nile Virus New York Isolate (WNV-NY1999). J Infect Dis 2001, 184:809-816.
23. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004, 303:2019-2022.
24. Berman P.W., Murthy K.K., Wrin T., Vennari J.C., Cobb E.K., Eastman D.J., et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 1996, 173:52-59.
25. Boyer J., Ugen K., Wang B., Agadjanan M., Gilbert L., Bagarazzi M., et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 1997, 3:526-532.
26. Almond N., Kent K., Cranage M., Rud E., Clarke B., Stott J. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995, 345:1342-1344.
27. Daniel M.C., Kirchhoff F., Czajak S.C., Sehgal S., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258:1938-1941.
28. Berlioz-Torrent C., Shacklett B.L., Erdman L., Delamarre L., Bouchaert L., Sonigo P., et al. Interactions of the cytoplasmic domains of human and simian retrovial transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J Virol 1999, 73:1350-1359.
29. Bultmann A., Muranyi W., Seed B., Haas G. Identification of two sequences in the cytoplamic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression. J Virol 2001, 75:5263-5276.
30. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., et al. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296:2354-2360.
31. Zhang L., Carruthers C.D., He T., Huang Y., Cao Y., Wang G., et al. HIV-1 subtypes, coreceptor usage and CCR5 polymorphism. AIDS Res Hum Retroviruses 1997, 13:1357-1366.
32. Zhang L., Huang Y., He T., Cao Y., Ho D.D. HIV-1 subtype and second-receptor use. Nature 1996, 383:768-776.
33. Peeters M., Vincent R., Perret J.L., Lasky M., Patrel D., Liegeois F., et al. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:115-121.
34. Wang W.K., Dudek T., Essex M., Lee T.H. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc Natl Acad Sci U S A 1999, 96:4558-4562.